PMID- 31954268 OWN - NLM STAT- MEDLINE DCOM- 20201123 LR - 20201123 IS - 1525-5069 (Electronic) IS - 1525-5050 (Linking) VI - 104 IP - Pt A DP - 2020 Mar TI - Quality of life and its association with comorbidities and adverse events from antiepileptic medications: Online survey of patients with epilepsy in Australia. PG - 106856 LID - S1525-5050(19)31211-9 [pii] LID - 10.1016/j.yebeh.2019.106856 [doi] AB - OBJECTIVE: This study aimed to explore the quality of life (QoL) of adult patients with epilepsy (PwE) in Australia and its relationship with comorbidities and adverse events (AEs) from antiepileptic drugs (AEDs). METHODS: Cross-sectional surveys were completed by PwE, or carer proxies, recruited via the online pharmacy application MedAdvisor and Australian PwE Facebook groups from May to August 2018. Data were collected on demographics, epilepsy severity and management, AEs, comorbidities, and QoL (using the Patient-Weighted Quality of Life in Epilepsy Inventory [QOLIE-10-P] total score). Two linear regression models were constructed to explore associations between AEs or comorbidities and QOLIE-10-P score, with possible confounders determined using stepwise selection. RESULTS: Nine hundred and seventy-eight of 1267 responses were eligible (mean age of respondents: 44.5 years, 64% female, 52% employed). Recent AED use was reported by 97%; 47% were on AED monotherapy, 35% had 1 year. After stepwise selection, control variables included in both models were time since diagnosis, employment status, seizure frequency, number of currently prescribed AEDs, and number of general practitioner (GP) visits per year. In the model for comorbidities, "psychiatric disorders" was associated with the largest QOLIE-10-P score decrease (-23.14, p < 0.001). In the model for AEs, which additionally controlled for depression and anxiety disorder, self-reported "memory problems" was associated with the largest decrease in QOLIE-10-P score (-14.27, p < 0.001). CONCLUSIONS: In this survey of Australian PwE, many of whom had relatively well-controlled epilepsy, psychiatric and self-reported memory problems were common and associated with the greatest detrimental impact on QoL. Further research is needed to better understand the underlying causes of impaired QoL and thereby improve its management. CI - Copyright (c) 2019 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Welton, Jeremy M AU - Welton JM AD - UCB Pharma, Level 1/1155 Malvern Rd, Malvern, VIC 3144, Australia. Electronic address: Jeremy.Welton@ucb.com. FAU - Walker, Christine AU - Walker C AD - Chronic Illness Alliance, 587 Canterbury Rd, Surrey Hills, VIC 3127, Australia. Electronic address: cwalker@chronicillness.org.au. FAU - Riney, Kate AU - Riney K AD - Queensland Children's Hospital, 501 Stanley St, South Brisbane, QLD 4101, Australia; University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia. Electronic address: drkateriney@qldkidsneuro.com. FAU - Ng, Alvin AU - Ng A AD - Costello Medical Singapore Pte Ltd, 133 New Bridge Road #23-01/02, Chinatown Point, 059413, Singapore. Electronic address: alvin.ng@costellomedical.com. FAU - Todd, Lisa AU - Todd L AD - Epilepsy Action Australia, 1/1 Lucknow Rd, North Ryde, NSW 2113, Australia. Electronic address: LTodd@epilepsy.org.au. FAU - D'Souza, Wendyl J AU - D'Souza WJ AD - The Department of Medicine, St Vincent's Hospital, 41 Victoria Parade, Fitzroy, VIC 3065, Australia; The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200115 PL - United States TA - Epilepsy Behav JT - Epilepsy & behavior : E&B JID - 100892858 RN - 0 (Anticonvulsants) SB - IM MH - Adult MH - Anticonvulsants/*adverse effects/therapeutic use MH - Australia/epidemiology MH - Caregivers/psychology MH - Comorbidity MH - Cross-Sectional Studies MH - Epilepsy/drug therapy/*epidemiology/*psychology MH - Female MH - Humans MH - Male MH - Memory Disorders/chemically induced MH - Mental Disorders/chemically induced MH - Middle Aged MH - Quality of Life/*psychology MH - Self Report MH - *Surveys and Questionnaires OTO - NOTNLM OT - Adverse events OT - Antiepileptic drugs OT - Australia OT - Comorbidities OT - Cross-sectional OT - Quality of life COIS- Declaration of competing interest JW is an employee of UCB Pharma. CW is CEO of Chronic Illness Alliance Inc. Australia and Board member of Epilepsy Foundation Australia. CW has received funding from UCB Pharma to contribute to this research. KR has received speaker honoraria, travel support, advisory board honoraria, and/or research funding from: UCB Pharma, Eisai Australia, Novartis Pharmaceuticals, Zogenix International Inc., AFT Pharmaceuticals Ltd., LivaNova Australia Pty Ltd., and Janssen-Cilag Pty Ltd. AN is an employee of Costello Medical Singapore Pte Ltd., which provided data analysis and editorial services for the study. LT is an employee of Epilepsy Action Australia and has no disclosures to declare. WD's salary is part-funded by The University of Melbourne. He has received travel, investigator-initiated, and speaker honoraria from UCB Pharma; investigator and speaker honoraria from Eisai Australia; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and Sanofi-Synthelabo; educational, travel, and fellowship grants from GSK Neurology Australia; advisory board honoraria from LivaNova PLC and Tilray Inc.; and honoraria from ScieGen Pharmaceuticals. EDAT- 2020/01/19 06:00 MHDA- 2020/11/24 06:00 CRDT- 2020/01/19 06:00 PHST- 2019/11/13 00:00 [received] PHST- 2019/12/12 00:00 [revised] PHST- 2019/12/12 00:00 [accepted] PHST- 2020/01/19 06:00 [pubmed] PHST- 2020/11/24 06:00 [medline] PHST- 2020/01/19 06:00 [entrez] AID - S1525-5050(19)31211-9 [pii] AID - 10.1016/j.yebeh.2019.106856 [doi] PST - ppublish SO - Epilepsy Behav. 2020 Mar;104(Pt A):106856. doi: 10.1016/j.yebeh.2019.106856. Epub 2020 Jan 15.